Syndax Pharmaceuticals Earnings

Syndax Pharmaceuticals’s revenue jumped 791.68% since last year same period to $68.48Mn in the Q4 2025. On a quarterly growth basis, Syndax Pharmaceuticals has generated 49.29% jump in its revenue since last 3-months.

Syndax Pharmaceuticals’s net profit jumped 27.77% since last year same period to $-68.01Mn in the Q4 2025. On a quarterly growth basis, Syndax Pharmaceuticals has generated -12.02% fall in its net profits since last 3-months.

Syndax Pharmaceuticals’s net profit margin jumped 91.9% since last year same period to -99.32% in the Q4 2025. On a quarterly growth basis, Syndax Pharmaceuticals has generated 24.96% jump in its net profit margins since last 3-months.

Syndax Pharmaceuticals’s earning per share (EPS) estimates for the current quarter stand at -0.6 - a -2.07% fall from last quarter’s estimates.

Syndax Pharmaceuticals’s earning per share (EPS) estimates for the current year stand at -0.6.

Syndax Pharmaceuticals’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Syndax Pharmaceuticals has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.